Transient orexin receptor blockade induces sleep without cataplexy
This article has no abstract so we have provided the first paragraph of the full text.
The orexin neuropeptides are well conserved across mammalian species, and contribute to regulation of the sleep–wake cycle. Deficits in endogenous orexin tone have been implicated in the pathophysiology of narcolepsy. Brisbare-Roch et al. have now investigated the effects of an oral antagonist of the orexin OX1 and OX2 receptors (ACT-078573; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland) on sleep-related variables.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
HighlightsClinical Pharmacology & Therapeutics News and Views
Orexins: looking forward to sleep, back at addictionNature Medicine News and Views (01 Feb 2007)
See all 5 matches for News And Views